Auvelity treats agitation associated with Alzheimer’s dementia by combining dextromethorphan and bupropion, two medicines that affect brain signaling involved in mood, arousal, and behavior. Dextromethorphan acts at NMDA and sigma-1 receptors, while bupropion slows its breakdown and increases its availability in the body. The exact reason this reduces agitation is not fully understood. In practice, a person who repeatedly paces, shouts, or becomes physically aggressive may have fewer or less frequent episodes after taking Auvelity on a scheduled basis. The U.S.
Food and Drug Administration approved Auvelity for agitation associated with dementia due to Alzheimer’s disease in adults in April 2026. It is the first approved non-antipsychotic treatment for this indication. It does not cure Alzheimer’s disease, restore memory, or stop neurodegeneration, and it is not intended to calm an isolated episode immediately. FDA prescribing information specifies that Auvelity should not be used as an as-needed medication. Agitation can include excessive movement, pacing, shouting, resisting care, threatening language, or physical aggression. Medication may be considered when these behaviors cause substantial distress or danger and continue after correctable triggers—such as pain, constipation, infection, fatigue, hunger, medication effects, or an overstimulating environment—have been addressed.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How Does Auvelity Treat Agitation Associated With Alzheimer’s Dementia?
- Auvelity’s Two-Drug Mechanism and Its Limitations
- Evidence for Auvelity in Alzheimer’s Agitation
- Starting Auvelity and Monitoring Daily Behavior
- Side Effects, Contraindications, and Drug Interactions
- Auvelity Compared With Antipsychotic Treatment and Non-Drug Care
- Deciding Whether Auvelity Is Providing a Meaningful Benefit
- Frequently Asked Questions
How Does Auvelity Treat Agitation Associated With Alzheimer’s Dementia?
auvelity contains dextromethorphan hydrobromide and bupropion hydrochloride. Dextromethorphan is an uncompetitive antagonist at the NMDA receptor, which is part of the brain’s glutamate signaling system, and an agonist at the sigma-1 receptor. These actions may help regulate neural networks involved in emotional control, perception, and behavioral responses. The FDA-approved label is careful to state that the precise mechanism responsible for improving Alzheimer’s agitation remains unclear. Bupropion has a supporting pharmacologic role.
It inhibits the CYP2D6 enzyme that normally metabolizes dextromethorphan, allowing dextromethorphan to remain at higher levels for longer. Bupropion also has activity involving norepinephrine and dopamine, although it is not known how much that activity contributes to the treatment of agitation. This combination is different from simply giving a person an over-the-counter cough medicine containing dextromethorphan. Cough products may contain different doses, additional ingredients, or formulations that do not produce the same exposure. For example, adding a dextromethorphan cough syrup to prescribed Auvelity could raise the risk of confusion, excessive sleepiness, serotonin syndrome, or overdose.
Auvelity’s Two-Drug Mechanism and Its Limitations
Glutamate helps nerve cells communicate, but disrupted glutamate signaling has been associated with several neurological and psychiatric symptoms. By modulating an NMDA receptor rather than blocking dopamine receptors in the way antipsychotic medications do, Auvelity offers a different route for treating agitation. Its sigma-1 receptor activity may also influence cellular stress responses and communication between brain networks, but these proposed effects do not prove that the drug protects brain cells or alters the course of Alzheimer’s disease. The medication targets agitation as a symptom cluster. It is not a treatment for every form of distress in dementia.
A person pulling at clothing because of an itchy rash, striking a caregiver because of an untreated urinary infection, or pacing because the room is too hot needs the underlying problem addressed. Suppressing behavior without investigating a sudden change can delay treatment of delirium, pain, dehydration, medication toxicity, or infection. There is also no guarantee that every form of agitation will improve. Someone may pace less while continuing to resist bathing, or verbal outbursts may decline without eliminating nighttime wandering. Goals should therefore be specific and observable rather than framed as making the person generally “calmer.”.
Evidence for Auvelity in Alzheimer’s Agitation
FDA approval was based on two randomized studies. In a five-week placebo-controlled trial, 152 participants received Auvelity and 156 received placebo. Agitation was measured with the Cohen-Mansfield Agitation Inventory, or CMAI, a 29-item scale based on caregiver reports of behaviors such as pacing, screaming, hitting, and repetitive movements. Scores can range from 29 to 203, with higher scores indicating more severe agitation. The average CMAI score decreased by 14.9 points with Auvelity and by 11.6 points with placebo, producing an adjusted treatment difference of 3.3 points in favor of Auvelity.
The sizeable improvement in the placebo group is an important limitation: structured attention, caregiver support, environmental changes, and symptoms fluctuating naturally can all influence behavior during a trial. The study lasted only five weeks, so it did not by itself establish years of effectiveness. A second study used a randomized-withdrawal design. Participants who had already shown a sustained response to Auvelity either continued it or switched to placebo. Those who continued treatment went longer before agitation relapsed. This supports maintenance of benefit among responders, but it does not tell clinicians what percentage of all newly treated patients will respond because only known responders entered the randomized phase.
Starting Auvelity and Monitoring Daily Behavior
For Alzheimer’s agitation, the labeled starting dose is 30 milligrams of dextromethorphan with 105 milligrams of bupropion once each morning. On day eight, the dose may increase to 30/105 milligrams twice daily, at least eight hours apart, if tolerated. On day 15, it may increase to 45/105 milligrams twice daily, again based on tolerability. The tablets can be taken with or without food but must be swallowed whole rather than crushed, divided, or chewed. This gradual schedule trades speed for tolerability. A rapid dose increase might seem attractive when aggression is disrupting care, but an older adult who develops dizziness, sleepiness, or confusion may become less safe rather than more manageable.
People with moderate kidney impairment, known poor CYP2D6 metabolism, or treatment with a strong CYP2D6 inhibitor have lower recommended maximum dosing. Auvelity is not recommended in severe kidney or severe liver impairment. Caregivers can keep a short behavior log before and after treatment begins. Instead of writing “bad afternoon,” they might record three episodes of shouting during personal care, 40 minutes of pacing after dinner, and one attempt to hit a caregiver. The same log should note sleep, bowel movements, pain signals, medication changes, and falls. This makes it easier to distinguish a meaningful treatment response from ordinary day-to-day variation.
Side Effects, Contraindications, and Drug Interactions
In the five-week Alzheimer’s agitation study, dizziness occurred in 9% of Auvelity-treated participants and 3% of those receiving placebo. Sleepiness, indigestion, fatigue, nausea, constipation, psychotic symptoms, and confusion were also reported more often with Auvelity than with placebo. Dizziness is especially consequential in dementia because a seemingly modest balance problem can lead to a fall, fracture, hospitalization, or loss of mobility. Bupropion can cause seizures, and risk rises with dose and with other seizure-threshold-lowering factors. Auvelity must not be used in someone with a seizure disorder, a current or previous diagnosis of anorexia nervosa or bulimia, or abrupt withdrawal from alcohol, benzodiazepines, barbiturates, or antiseizure medication.
It can raise blood pressure, so blood pressure should be assessed before treatment and monitored periodically. Older adults may also be more vulnerable to hyponatremia, which can present as new confusion, weakness, unsteadiness, headache, or seizures. Medication reconciliation is essential. Auvelity should not be combined with a monoamine oxidase inhibitor, and a 14-day separation is generally required when switching to or from an MAOI. Combining it with SSRIs, tricyclic antidepressants, or other serotonergic drugs can increase the risk of serotonin syndrome, with possible restlessness, fever, sweating, tremor, muscle jerking, high blood pressure, or altered mental status. Caregivers should also check labels on cough remedies because many contain dextromethorphan, while certain antidepressants and smoking-cessation products contain bupropion.
Auvelity Compared With Antipsychotic Treatment and Non-Drug Care
Auvelity differs from brexpiprazole, the antipsychotic also approved for agitation associated with Alzheimer’s dementia. Antipsychotics affect dopamine and other receptors and carry a boxed warning about increased mortality in older adults with dementia-related psychosis. Auvelity is not an antipsychotic, but that does not make it free of serious risks; seizures, elevated blood pressure, falls, serotonin syndrome, neuropsychiatric reactions, and low sodium remain relevant.
Non-drug care is not interchangeable with medication because it addresses triggers that a prescription cannot correct. For example, if agitation reliably starts when two caregivers give rapid instructions during bathing, slowing the process, warming the room, covering exposed areas, and assigning one person to speak may reduce distress. Medication can be added when such measures are insufficient, but it should not replace attention to comfort, communication, routine, and the environment.
Deciding Whether Auvelity Is Providing a Meaningful Benefit
A treatment trial should have predefined targets, such as fewer attempts to strike staff, shorter pacing episodes, safer completion of dressing, or less frequent nighttime shouting. Clinicians should review these targets after dose changes and periodically thereafter, while also checking blood pressure, falls, alertness, appetite, gastrointestinal symptoms, and new confusion.
A lower behavior score is not a satisfactory trade if the person becomes too dizzy to walk safely or too sleepy to participate in meals. New agitation that develops over hours or a few days requires medical assessment rather than an automatic dose increase. A caregiver who notices sudden yelling together with fever, painful urination, marked drowsiness, one-sided weakness, breathing difficulty, or a recent fall should seek prompt clinical help because infection, stroke, injury, or delirium may be responsible.
Frequently Asked Questions
Is Auvelity approved for Alzheimer’s agitation?
Yes. The FDA approved Auvelity in 2026 to treat agitation associated with dementia due to Alzheimer’s disease in adults. Its dosing for agitation differs from the schedule originally approved for major depressive disorder.
Can Auvelity be given only when agitation occurs?
No. The prescribing information specifically states that it is not an as-needed treatment. It is taken on a scheduled basis and gradually increased according to tolerability.
Does Auvelity slow Alzheimer’s disease?
No. It treats agitation associated with Alzheimer’s dementia but has not been shown to remove amyloid, restore lost memory, or slow the underlying neurodegenerative process.
How quickly does Auvelity work?
The principal short-term study measured improvement over five weeks. Individual responses can emerge at different times, and dose titration takes at least two weeks to reach the labeled maximum when tolerated.
What symptoms require urgent attention?
A seizure, fainting, severe confusion, high fever with tremor or muscle jerking, suicidal behavior, severe allergic symptoms, or signs of stroke require urgent medical evaluation. Sudden agitation accompanied by fever, pain, or a major change in alertness should also be assessed for delirium or illness.
Can Auvelity be crushed for someone who has trouble swallowing?
No. The extended-release tablets must be swallowed whole and should not be crushed, divided, or chewed. A prescriber or pharmacist should be consulted if swallowing is unsafe.
